मिटापिवैट और नेफाज़ोडोन का इंटरैक्शन

Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.

Moderate CYP3A Inhibitors: Avoid concomitant use.

Prevention or Management Avoid co-administration of strong CYP3A inhibitors with AQVESME [see Dosage and Administration (2.4) ] .

Prevention or Management Avoid co-administration of moderate CYP3A inhibitors with AQVESME [see Dosage and Administration (2.4) ] .

Effect of Other Drugs on AQVESME Strong CYP3A Inhibitors Clinical Impact Co-administration of AQVESME with strong CYP3A inhibitors increased mitapivat plasma concentrations [see Clinical Pharmacology (12.3) ] .